Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 12, 2025
Discovery & Translation
Science Spotlight: Killing the mesenchymal precursors that drive cancer progression
BioCentury’s roundup of translational innovations also includes blood detection of pregnancy complications, BBB-crossing antibodies, and more
BioCentury | Aug 5, 2022
Finance
Aug. 4 Quick Takes: Forbion, Sofinnova lead F2G’s $70M financing
Plus newco emerges from Daley lab and updates Lilly, Pfizer, Regeneron, Arucs-Gilead, Travere, BioCryst and more
BioCentury | Jun 18, 2021
Finance
Singapore-based EVX launches Nuevocor with $24M series A to advance cardiomyopathy gene therapy pipeline
BioCentury | Mar 13, 2021
Translation in Brief
NIH identifies antisense oligos to treat progeria; plus epigenetic gene therapies for chronic pain and Cend’s pancreatic cancer therapy
BioCentury’s roundup of translational news
BioCentury | Jan 30, 2021
Distillery Therapeutics
CRISPR base editing to treat progeria
DISEASE CATEGORY: Other
INDICATION: Progeria A team led NIH Director Francis Collins, CRISPR pioneer David Liu, and Vanderbilt University’s Jonathan Brown showed that a CRISPR adenine base
INDICATION: Progeria A team led NIH Director Francis Collins, CRISPR pioneer David Liu, and Vanderbilt University’s Jonathan Brown showed that a CRISPR adenine base
BioCentury | Jul 31, 2018
Translation in Brief
Satellite damage
How satellite RNAs could cause cancer by promoting mutations
Items per page:
1 - 10 of 13